Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
In this Phase III study, Pharm-Olam partnered with a progressive company to help find a better solution for those suffering with this deadly, rare disease.
Allergic rhinitis affects between 10% and 25% of the worldwide population, and is observed most in ecologically unfavorable regions. See our study for more.
Glioblastoma / Anaplastic Astrocytoma Case Study
Glioblastoma / Anaplastic Astrocytoma is a brain tumor with very few available therapies. Learn more about our search for effective treatment options.
Recruitment of Patients in a Phase III Systemic Lupus Erythematosus Study
SLE is a notoriously difficult-to-diagnose autoimmune disorder with no known cure. Our study aimed to find a treatment for severe cases of the disorder.
Rescue and Transfer of a Bioequivalence Breast Cancer Study
Pharm-Olam was called on to rescue a Breast Cancer bioequivalence study. Learn how this transition process successfully supported the study sponsor.
Accuracy and Compliance in a Phase I/II Trial Involving Preterm Neonates
Pharm-Olam provided clinical research services on a pediatric Respiratory Distress Syndrome study. Discover the unique challenges and solutions involved.
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Pharm-Olam provided a complete enrollment solution for this ABSSSI study. Learn how Pharm-Olam’s efficiency allowed for a quick turnaround in this study.
Systemic Lupus Erythematosus with Lupus Nephritis (Orphan)
Learn how Pharm-Olam overcame difficult enrollment challenges in a massive Systemic Lupus Erythematosus trial and earned high praise from the sponsor.
Automated Sample Retention Solution for BA/BE Studies
BA/BE studies require samples of the investigational product to be retained. Learn about Pharm-Olam’s automated solution that saves time and resources.
Birch and Grass Pollen Allergy Studies
Learn how Pharm-Olam handled challenges such as unpredictable seasons and high patient withdrawal rates in these Birch and Grass Pollen Allergy studies.
Post Herpetic Neuralgia
Pharm-Olam’s experience level and proactive approach were critical in the speedy recruitment of patients for this Phase II Post Herpetic Neuralgia study.
Acute Bacterial and Skin Structure Infections (Phase IV and Oral)
Pharm-Olam completed enrollment using only 41 out of the 49 planned sites in this study. Find out what the sponsor had to say about the efficiency of our services.
Pulmonary Arterial Hypertension in Eastern Europe
Pharm-Olam played an integral part in the enrollment of the additional patients in this Phase III study. Discover how we met and surpassed those goals.